Happy to see this teamwork out ! 🎉 Special kudos to Eugenio Galli, of course🙌 Briefly, n = 254 Use of propensity score => ICANS prophylaxis w/ Levetiracetam offers NO BENEFIT in CD19 CAR-T for LBCL, but is associated with higher incidence of ICAHT! ashpublications.org/bloodadvances/…

#Hematology Combined PET and #ctDNA response as a predictor of POD24 for follicular #lymphoma after first-line induction treatment #lymsm ashpublications.org/blood/article/…

CONGRESS | #SOHO2025 | PRESENTATION Jeremy S. Abramson, MassGeneral News discusses the use of bispecific antibodies in patients with aggressive B-cell lymphoma. They highlight results from the STARGLO trial, which showed that Glofit-GemOx improved PFS and OS vs R-GemOx in

CONGRESS | #SOHO2025 | POSTER Alex Herrera, City of Hope presents an overview of the phase III GOLSEEK-4 trial of golcadomide + rituximab vs investigator’s choice in patients with R/R FL who have received ≥1 prior line of therapy (N = 400). Enrollment is currently ongoing, and

CONGRESS | #SOHO2025 | PRESENTATION Adam Olszewski Adam Olszewski MD Brown University presents primary results from the phase III SUNMO trial of evaluating mosunetuzumab + polatuzumab vedotin (Mosun-Pola) vs rituximab + gemcitabine + oxaliplatin (R-GemOx) in auto-HSCT ineligible

CONGRESS | #SOHO2025 | PRESENTATION Juan P. Alderuccio Sylvester Comprehensive Cancer Center Miller Medicine discusses initial results from the phase Ib LOTIS-7 trial of loncastuximab tesirine + glofitamab in patients with R/R DLBCL. The safety profile was manageable, with encouraging initial efficacy

Dr. Juan Pablo Alderuccio presenting at #SOHO25 the Ph. 1b data of the LOTIS-7 trial (lonca + glofi in R/R DLBCL): - 93.3% ORR and a CR rate of 86.7% - No grade 5 TAEs and median time to first response (CR or PR) was 42 days - Rates of CRS and ICANS were low #lymsm

1/ Adam Olszewski updating at #SOHO25 SUNMO (mosun + pola versus R-GemOx in ASCT-ineligible R/R LBL) #lymsm

CONGRESS | #SOHO2025 | PRESENTATION Alex Herrera, City of Hope, shared insights on the evolving standard of care for advanced stage Hodgkin #lymphoma. They emphasized that the standard has shifted in recent years, with N-AVD and BrECADD emerging as the preferred regimens,

CONGRESS | SOHO 2025 | PRESENTATION Adam Olszewski Adam Olszewski MD Brown University presents primary results from the phase III SUNMO trial evaluating mosunetuzumab + polatuzumab vedotin (Mosun-Pola) vs rituximab + gemcitabine + oxaliplatin (R-GemOx) in auto-HSCT ineligible patients

Olanzapine, when tolerated (I usually dose escalate from 2.5 mg) should be standard for cachexia, appetite, nausea. Still seeing megace, mirtazapine recommended despite essentially no evidence. We need more supportive onc education for our hem inc practitioners and fellows.

Updates from MajesTEC-5: Continue to see unprecedented mrd negativity rates after just 6 cycles of teclistamab + Dara-R and +\- bortezomib. Pretty clear that bortezomib thus far not offering benefit. Is transplant really needed either? Infection rates a bit concerning with short

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial ashpublications.org/blood/article-…

The 2025 LBCL Guidelines are out ! Fantastic work made by the European Hematology Association Cc C. Thieblemont doi.org/10.1002/hem3.7…

🧵 EHA 2025 Clinical Practice Guidelines for Large B-Cell Lymphoma (LBCL) 1️⃣ Diagnosis & Baseline 🧬 🔹 Biopsy (excisional preferred) 🔹 PET-CT for staging 🔹 IPI & CNS-IPI mandatory 🔹 Molecular: MYC, BCL2/BCL6 (DH/TH) ➡️ poor prognosis 🔹 Baseline MRI/CSF if CNS risk #LBCL

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Hot off the press! Lewis et al. Wonderful to see this international investigator initiated academic RCT published open access in The Lancet today Fantastic UK+Nordic collaboration #MCL #Lymsm thelancet.com/journals/lance…

🚫💉 End of chemo in mantle is here ? ENRICH trial (Lancet 2025) 👥 397 untreated MCL (≥60 yrs) 💊 Ibrutinib + Rituximab (IR) vs 💉Immunochemotherapy (R-CHOP / R-Benda) 📊 Primary endpoint: PFS • IR > Chemo — HR 0.69 (0.52–0.90), p = 0.0034 • 🔹 vs R-CHOP HR 0.37

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-cell Lymphoma: Primary Results of the Phase 3 SUNMO Trial. Co-authored by Jason Westin, MD FACP FASCO Read the full article brnw.ch/21wWoAi #lymsm

Neelapu - long term zuma5 FU, axi-cel in iNHL (mainly FL) • 159 pts, 5y FU • 75% CRR, median PFS 62.2mo • NRM 15% • ongoing response correlated with enriched naive T-cells in axi-cel product. #lymsm ascopubs.org/doi/10.1200/JC…